vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and Marathon Bancorp, Inc. (MBBC). Click either name above to swap in a different company.
Marathon Bancorp, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.6M, roughly 1.4× Atara Biotherapeutics, Inc.). On growth, Marathon Bancorp, Inc. posted the faster year-over-year revenue change (41.7% vs -95.1%). Over the past eight quarters, Marathon Bancorp, Inc.'s revenue compounded faster (20.3% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Marathon Bancorp, Inc. is a Maryland-based financial holding company that primarily operates through its community bank subsidiary. It offers a full range of retail and commercial banking products including deposit accounts, consumer loans, commercial mortgages, and small business financing, serving individual and small-to-medium enterprise customers across local markets in Maryland.
ATRA vs MBBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.2M |
| Net Profit | — | $501.4K |
| Gross Margin | — | — |
| Operating Margin | — | 26.2% |
| Net Margin | — | 22.3% |
| Revenue YoY | -95.1% | 41.7% |
| Net Profit YoY | 73.2% | 880.7% |
| EPS (diluted) | — | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $2.2M | ||
| Q3 25 | $3.5M | $2.1M | ||
| Q2 25 | $17.6M | $1.9M | ||
| Q1 25 | $98.1M | $1.7M | ||
| Q4 24 | $32.8M | $1.6M | ||
| Q3 24 | $40.2M | $1.6M | ||
| Q2 24 | $28.6M | $1.6M | ||
| Q1 24 | $27.4M | $1.6M |
| Q4 25 | — | $501.4K | ||
| Q3 25 | $-4.3M | $444.3K | ||
| Q2 25 | $2.4M | $-332.0K | ||
| Q1 25 | $38.0M | $148.4K | ||
| Q4 24 | $-12.7M | $51.1K | ||
| Q3 24 | $-21.9M | $174.9K | ||
| Q2 24 | $-19.0M | $85.8K | ||
| Q1 24 | $-31.8M | $-631.1K |
| Q4 25 | — | 26.2% | ||
| Q3 25 | -103.5% | 25.5% | ||
| Q2 25 | 18.2% | -25.7% | ||
| Q1 25 | 39.5% | 11.6% | ||
| Q4 24 | -37.3% | 3.3% | ||
| Q3 24 | -54.1% | 13.4% | ||
| Q2 24 | -63.7% | 4.1% | ||
| Q1 24 | -114.2% | -53.7% |
| Q4 25 | — | 22.3% | ||
| Q3 25 | -124.6% | 20.7% | ||
| Q2 25 | 13.6% | -18.9% | ||
| Q1 25 | 38.7% | 8.9% | ||
| Q4 24 | -38.8% | 3.2% | ||
| Q3 24 | -54.5% | 10.8% | ||
| Q2 24 | -66.5% | 6.2% | ||
| Q1 24 | -116.1% | -40.7% |
| Q4 25 | — | $0.19 | ||
| Q3 25 | $-0.32 | $0.17 | ||
| Q2 25 | $0.19 | $-0.13 | ||
| Q1 25 | $3.50 | $0.07 | ||
| Q4 24 | $0.27 | $0.02 | ||
| Q3 24 | $-2.93 | $0.06 | ||
| Q2 24 | $-3.10 | $0.07 | ||
| Q1 24 | $-5.65 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $46.9M |
| Total Assets | $20.2M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $13.7M | — | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $13.8M | — | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $35.3M | — | ||
| Q1 24 | $46.2M | — |
| Q4 25 | $-38.5M | $46.9M | ||
| Q3 25 | $-36.6M | $46.3M | ||
| Q2 25 | $-35.0M | $45.7M | ||
| Q1 25 | $-55.1M | $32.0M | ||
| Q4 24 | $-97.3M | $31.7M | ||
| Q3 24 | $-90.5M | $31.6M | ||
| Q2 24 | $-110.9M | $31.3M | ||
| Q1 24 | $-98.3M | $31.4M |
| Q4 25 | $20.2M | $248.0M | ||
| Q3 25 | $30.2M | $246.0M | ||
| Q2 25 | $36.9M | $238.8M | ||
| Q1 25 | $62.0M | $236.8M | ||
| Q4 24 | $109.1M | $217.9M | ||
| Q3 24 | $142.7M | $216.5M | ||
| Q2 24 | $117.3M | $219.3M | ||
| Q1 24 | $165.3M | $225.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $1.4M |
| Free Cash FlowOCF − Capex | — | $1.4M |
| FCF MarginFCF / Revenue | — | 62.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 2.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $1.4M | ||
| Q3 25 | $-9.8M | $464.0K | ||
| Q2 25 | $-7.3M | $1.4M | ||
| Q1 25 | $-28.1M | $849.0K | ||
| Q4 24 | $-24.5M | $113.6K | ||
| Q3 24 | $-4.0M | $945.2K | ||
| Q2 24 | $-10.6M | $416.6K | ||
| Q1 24 | $-29.6M | $-802.1K |
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $456.6K | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $773.2K | ||
| Q4 24 | $-24.6M | $105.0K | ||
| Q3 24 | — | $921.6K | ||
| Q2 24 | $-10.7M | $-1.8M | ||
| Q1 24 | $-29.7M | $-1.1M |
| Q4 25 | — | 62.3% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | — | 66.0% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | -75.0% | 6.6% | ||
| Q3 24 | — | 57.1% | ||
| Q2 24 | -37.3% | -118.5% | ||
| Q1 24 | -108.7% | -67.9% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 9.3% | ||
| Q1 25 | 0.0% | 4.5% | ||
| Q4 24 | 0.3% | 0.5% | ||
| Q3 24 | 0.0% | 1.5% | ||
| Q2 24 | 0.1% | 145.2% | ||
| Q1 24 | 0.5% | 16.2% |
| Q4 25 | — | 2.82× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | 5.72× | ||
| Q4 24 | — | 2.22× | ||
| Q3 24 | — | 5.40× | ||
| Q2 24 | — | 4.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
